March 26, 2024 Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC March 12, 2024 Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules March 11, 2024 Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules March 1, 2024 Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024 February 28, 2024 Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway February 16, 2024 Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement February 9, 2024 Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights February 5, 2024 Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds February 2, 2024 Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results January 30, 2024 Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates
March 26, 2024 Intelligent Bio Solutions to Present at the LD Micro Invitational XIV Investor Conference on April 9 in NYC
March 12, 2024 Intelligent Bio Solutions Announces Closing of $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 11, 2024 Intelligent Bio Solutions Announces $10.1 Million Private Placement Priced At-the-Market Under Nasdaq Rules
March 1, 2024 Intelligent Bio Solutions Inc. to Present at the Emerging Growth Conference on March 6, 2024
February 28, 2024 Intelligent Bio Solutions Partners with Cliantha Research to Conduct Clinical Study as Part of FDA 510(k) Pathway
February 16, 2024 Intelligent Bio Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement and Confirms Compliance with Minimum Stockholders’ Equity Requirement
February 9, 2024 Intelligent Bio Solutions Inc. Reports Fiscal Second Quarter and Six-Month Financial Results and Operational Highlights
February 5, 2024 Intelligent Bio Solutions Inc. Announces Exercise of Previously Issued Warrants for $1.77 Million in Gross Proceeds
February 2, 2024 Intelligent Bio Solutions Inc. Announces Preliminary Unaudited Fiscal Second Quarter and Six-Month Revenue Results
January 30, 2024 Fingerprint Drug Test Delivers Quantifiable Benefits for Customers as Adoption in Workplaces Accelerates
